Table 1.
Epithelial ovarian cancer (EOC) patient cohorts for the development and validation of integrated predictors for patient response to standard chemotherapy drugs.
Figure 1.
Integrated co-expression extrapolation (COXEN) gene expression model (predictor) development and validation procedures.
Table 2.
Logistic regression analysis for the paclitaxel prediction of primary chemotherapy response.
Table 3.
Cox regression survival analysis for the prediction of patient survival after primary and secondary chemotherapies.
Figure 2.
Kaplan-Meier survival analysis of predicted responders and nonresponders among recurrent EOC patients.
(A) paclitaxel predictor prediction for OS in TCGA-448, (B) cyclophosphamide predictor prediction for OS in TCGA-448, (C) topotecan predictor prediction for OS in TCGA-test.
Table 4.
Clinical response rates of COXEN-matched vs. unmatched patient groups in the TCGA cohort after the primary platinum-based chemotherapy.
Figure 3.
Kaplan-Meier survival stratification between COXEN-matched and unmatched patients in the TCGA-448 cohort.
(A) OS difference between matched and unmatched patients, (B) PFS difference between matched and unmatched patients, (C) OS difference between matched and unmatched patients among recurrent EOC patients.